Source: GlobeNewswire

Press Release: Organovo : Organovo Affirms Key Clinical Development Goals; Company Reports Fiscal Third-Quarter 2019 Results

SAN DIEGO, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo"), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today affirmed its key clinical development goals and reported its fiscal third-quarter 2019 financial results.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Based on data from Organovo's latest SEC filings

Annual Revenue

Based on data from Organovo's latest SEC filings

Employees

Taylor J. Crouch's photo - President & CEO of Organovo

President & CEO

Taylor J. Crouch

CEO Approval Rating

71/100

Organovo develops tissue and disease models for medical research and therapeutic applications.

Organovo is headquartered ...
Read more